Physician profile
Robert D Anderson
NPI 1255586400
$14,378.46
in general payments reported to CMS, 2019-2025
48 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $1,480 · 2021: $1,995 · 2022: $1,600 · 2023: $2,099 · 2024: $2,947 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,008.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,970.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,898.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,395.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,125.24 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $978.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $920.86 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $826.51 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $680.77 | 2020-2025 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $534.30 | 2022-2025 | |
| Exact Sciences Corporation | $423.33 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $346.03 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $287.83 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.64 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $279.14 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $238.26 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.